Post-Treatment Surveillance Workshop Highlights
Discussing post-treatment surveillance issues in cancer with a focus on imaging and liquid biopsies. The workshop aims to identify priorities for evaluation in clinical trials, including strategic priorities, trial prioritization, and implementation plans.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
NCI Workshop: Issues in Post-Treatment Surveillance Lalitha K. Shankar, MD, PhD, Cancer Imaging Program, NCI March 26, 2018
NCI Planning Committee Jeff Abrams, Barry Kramer, Paul Jacobsen (DCTD, DCP & DCCPS) Lalitha Shankar, Bhupinder Mann, Carmen Allegra, Shakuntala Malik, Larissa Korde, Nita Seibel, Worta McCaskill-Stevens and Anne Menkens
Conference Goals and Rationale: To discuss issues in post treatment surveillance given the current advances in imaging and liquid biopsies Specific discussions will occur in Breast, Colon, NSCLS, Prostate and Testicular cancer
Meeting Goals/Objectives Identify and prioritize histologies and tools that are most suitable to be evaluated in this setting, in NCTN and NCORP clinical trials Format: 1stmorning: Plenary sessions on Issues in Post-treatment surveillance from various perspectives 1stafternoon: Breakout sessions for the different cancer types 2ndMorning: Reports from breakout sessions and discussion
Meeting Outcomes Anticipated outputs from the meeting - Executive Summary - Strategic priorities for studies most appropriate for study in NCTN and NCORP trials (Phase II and III) - Trial prioritization - Implementation plan - Identification of questions that could be answered by registries
NCI Resources for Early Stage Clinical Evaluation of Diagnostic Tools PAR-18-629: Integration of Imaging and Fluid- Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) PAR-18-560: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis PAR-18-530: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) PAR-18-317: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
